Juan Francisco Jiménez Alonso-rekin lankidetzan egindako argitalpenak (9)

2016

  1. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies

    Seminars in Arthritis and Rheumatism, Vol. 45, Núm. 4, pp. 391-399

  2. Off-label use of rituximab for systemic lupus erythematosus in Europe

    Lupus Science and Medicine, Vol. 3, Núm. 1

  3. Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 34, Núm. 3, pp. 466-472

2013

  1. Belimumab en el lupus eritematoso sistémico: una guía para su uso en la práctica diaria

    Revista Clinica Espanola

  2. Recomendaciones sobre el uso de belimumab en el lupus eritematoso sistémico. Guía de Práctica Clínica GEAS-SEMI

    Revista Clinica Espanola, Vol. 213, Núm. 1, pp. 42-58

2012

  1. Diagnosis and treatment of Lupus nephritis: Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish society of internal medicine (SEMI) and the Spanish society of nephrology (S.E.N.)

    Nefrologia, Vol. 32, Núm. SUPPL. 1, pp. 1-45

  2. Diagnosis and treatment of lupus nephritis

    Revista Clinica Espanola

  3. Diagnóstico y tratamiento de la nefritis lúpica: El camino del consenso

    Revista Clinica Espanola, Vol. 212, Núm. 3, pp. 155-156

2010

  1. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases

    Clinical and Experimental Rheumatology, Vol. 28, Núm. 4, pp. 468-476